| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 13.64% | Citigroup | $1 → $1.5 | Maintains | Neutral |
| 03/06/2023 | 127.27% | Canaccord Genuity | $4 → $3 | Maintains | Buy |
| 03/06/2023 | -5.3% | Credit Suisse | $2.5 → $1.25 | Maintains | Underperform |
| 11/16/2022 | 36.36% | Citigroup | $3.5 → $1.8 | Maintains | Neutral |
| 11/08/2022 | 13.64% | SVB Leerink | $3 → $1.5 | Maintains | Market Perform |
| 08/09/2022 | 165.15% | Citigroup | $3 → $3.5 | Maintains | Neutral |
| 08/09/2022 | 127.27% | Credit Suisse | $3.5 → $3 | Maintains | Underperform |
| 05/10/2022 | 127.27% | SVB Leerink | $2.5 → $3 | Maintains | Market Perform |
| 02/25/2022 | 89.39% | SVB Leerink | $3 → $2.5 | Maintains | Market Perform |
| 02/02/2022 | 354.55% | Canaccord Genuity | → $6 | Initiates Coverage On | → Buy |
| 02/02/2022 | 127.27% | Cowen & Co. | $7 → $3 | Upgrades | Underperform → Market Perform |
| 01/19/2022 | 127.27% | SVB Leerink | → $3 | Initiates Coverage On | → Market Perform |
| 01/07/2022 | 165.15% | Credit Suisse | $9 → $3.5 | Downgrades | Neutral → Underperform |
| 11/15/2021 | 581.82% | Credit Suisse | $8 → $9 | Maintains | Neutral |
| 09/10/2021 | 430.3% | Cowen & Co. | → $7 | Initiates Coverage On | → Underperform |
| 07/12/2021 | 581.82% | JP Morgan | → $9 | Downgrades | Neutral → Underweight |
| 06/10/2021 | 657.58% | B of A Securities | → $10 | Downgrades | Neutral → Underperform |
| 05/19/2021 | 581.82% | Credit Suisse | $10 → $9 | Maintains | Neutral |
| 05/17/2021 | 581.82% | B of A Securities | $15 → $9 | Downgrades | Buy → Neutral |
| 03/09/2021 | 657.58% | Credit Suisse | → $10 | Initiates Coverage On | → Neutral |
| 02/02/2021 | 1339.39% | Citigroup | → $19 | Initiates Coverage On | → Buy |
| 02/01/2021 | 1036.36% | JP Morgan | → $15 | Initiates Coverage On | → Neutral |
What is the target price for Clover Health Investments (CLOV)?
The latest price target for Clover Health Investments (NASDAQ: CLOV) was reported by Citigroup on August 11, 2023. The analyst firm set a price target for $1.50 expecting CLOV to rise to within 12 months (a possible 13.64% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Clover Health Investments (CLOV)?
The latest analyst rating for Clover Health Investments (NASDAQ: CLOV) was provided by Citigroup, and Clover Health Investments maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Clover Health Investments (CLOV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clover Health Investments, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clover Health Investments was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
Is the Analyst Rating Clover Health Investments (CLOV) correct?
While ratings are subjective and will change, the latest Clover Health Investments (CLOV) rating was a maintained with a price target of $1.00 to $1.50. The current price Clover Health Investments (CLOV) is trading at is $1.32, which is within the analyst's predicted range.